Kyverna Therapeutics Upgraded to Buy by HC Wainwright Amid Upcoming Data Sets
ByAinvest
Thursday, May 29, 2025 6:47 am ET1min read
KYTX--
HC Wainwright upgraded Kyverna Therapeutics (KYTX) to Buy from Neutral, citing three upcoming data sets through mid-2025. The company expects a cash runway into 2027, with $242.6 million in cash, cash equivalents, and available-for-sale marketable securities. Analyst Mitchell S. Kapoor believes the risk-reward profile is attractive, particularly given the deeply negative enterprise value. Kapoor raised the price target from $4 to $5.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet